New treatments for myocardial fibrosis.
Sanderson
John E
JE
D000450:Aldosterone / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D002192:Canrenone / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004719:Endomyocardial Fibrosis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D006333:Heart Failure / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000150:complications; D051381:Rats; D013148:Spironolactone / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000450:Aldosterone; D002192:Canrenone